This post was published on ZYX Short Sell Change Alert We are repeating that conservative investors should not enter this trade. Even though the trial has failed and there is not enough life left in the patent, the disease evokes such emotion the some will continue to run up the stock.
This post was published on ZYX Short Sell Change Alert Consider adding another 10% tranche in the zone of $45.90 to $46.60.
This post was published on ZYX Short Sell Change Alert The stock is likely to be very volatile, conservative investors should not enter this trade. The results of the trial are being misinterpreted by some in the market. Here are the details. LLY announced that the primary endpoints, both cognitive and functional, were
This post was published on ZYX Short Sell Change Alert Stock moved right after the post. Most fills should be $43.87. Consider adding 10% around $43.80-44.50.
This post was published on ZYX Short Sell Change Alert LLY Alzheimer drug trial has failed. Consider starting a 10% tranche right here around $42.82. More later.
We are short diabetes stocks with following average sell prices: LLY 35.30, INCY 4.15, ALKS 9.20, AMLN 11.50 and ALXN 37.6 www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since
Based on our analysis of the presentations at American Diabetes Association’s Annual Meeting in New Orleans, we expect the following stocks to move : LLY, AMLN, ALKS, INCY, HALO,ALXN, MRK AND AZN. Data from all of the above companies is positive. We can easily analyze the data, but predicting the
Roche’s acquisition of DNA ( Genentech ) shows change of the company’s long practiced successful strategy by the new CEO. This indicates lack of confidence in the prior strategy. The new strategy is in reality integration of autonomous subsidiaries, although Roche does not characterize this way. We believe there will